The Concise Guide to PHARMACOLOGY 2019/20: G protein‐coupled receptors SPH Alexander, A Christopoulos, AP Davenport, E Kelly, A Mathie, ... British journal of pharmacology 176, S21-S141, 2019 | 775 | 2019 |
The Concise Guide to PHARMACOLOGY 2021/22: G protein‐coupled receptors SPH Alexander, A Christopoulos, AP Davenport, E Kelly, A Mathie, ... British journal of pharmacology 178, S27-S156, 2021 | 477 | 2021 |
Neuropharmacology of emesis induced by anti-cancer therapy PLR Andrews, WG Rapeport, GJ Sanger Trends in Pharmacological Sciences 9 (9), 334-341, 1988 | 472 | 1988 |
Inhibition of cisplatin‐induced vomiting by selective 5‐hydroxytryptamine M‐receptor antagonism WD Miner, GJ Sanger British journal of pharmacology 88 (3), 497-499, 1986 | 405 | 1986 |
Cloning and functional expression of a human orthologue of rat vanilloid receptor-1 P Hayes, HJ Meadows, MJ Gunthorpe, MH Harries, MD Duckworth, ... Pain 88 (2), 205-215, 2000 | 393 | 2000 |
The concise guide to pharmacology 2017/18: overview SPH Alexander, E Kelly, NV Marrion, JA Peters, E Faccenda, SD Harding, ... British journal of pharmacology 174, S1-S16, 2017 | 311 | 2017 |
Selective and functional 5-hydroxytryptamine3 receptor antagonism by BRL 43694 (granisetron) GJ Sanger, DR Nelson European journal of pharmacology 159 (2), 113-124, 1989 | 277 | 1989 |
Treatment of nausea and vomiting: gaps in our knowledge GJ Sanger, PLR Andrews Autonomic neuroscience 129 (1-2), 3-16, 2006 | 272 | 2006 |
Dorsal root ganglion neurons show increased expression of the calcium channel α2δ-1 subunit following partial sciatic nerve injury RA Newton, S Bingham, PC Case, GJ Sanger, SN Lawson Molecular Brain Research 95 (1-2), 1-8, 2001 | 260 | 2001 |
Growth hormone secretagogue receptors in rat and human gastrointestinal tract and the effects of ghrelin NB Dass, M Munonyara, AK Bassil, GJ Hervieu, S Osbourne, S Corcoran, ... Neuroscience 120 (2), 443-453, 2003 | 240 | 2003 |
The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694 J Bermudez, EA Boyle, WD Miner, GJ Sanger British journal of cancer 58 (5), 644-650, 1988 | 238 | 1988 |
The relationship between the effects of short‐chain fatty acids on intestinal motility in vitro and GPR43 receptor activation NB Dass, AK John, AK Bassil, CW Crumbley, WR Shehee, FP Maurio, ... Neurogastroenterology & Motility 19 (1), 66-74, 2007 | 224 | 2007 |
Abdominal vagal afferent neurones: an important target for the treatment of gastrointestinal dysfunction PLR Andrews, GJ Sanger Current opinion in pharmacology 2 (6), 650-656, 2002 | 203 | 2002 |
5-Hydroxytryptamine (5-HT3) receptor antagonists. 1. Indazole and indolizine-3-carboxylic acid derivatives J Bermudez, CS Fake, GF Joiner, KA Joiner, FD King, WD Miner, ... Journal of medicinal chemistry 33 (7), 1924-1929, 1990 | 195 | 1990 |
International Union of Basic and Clinical Pharmacology. CX. Classification of receptors for 5-hydroxytryptamine; pharmacology and function NM Barnes, GP Ahern, C Becamel, J Bockaert, M Camilleri, ... Pharmacological reviews 73 (1), 310-520, 2021 | 190 | 2021 |
Evidence that 5-hydroxytryptamine3 receptors mediate cytotoxic drug and radiation-evoked emesis WD Miner, GJ Sanger, DH Turner British journal of cancer 56 (2), 159-162, 1987 | 150 | 1987 |
Little or no ability of obestatin to interact with ghrelin or modify motility in the rat gastrointestinal tract AK Bassil, Y Häglund, J Brown, T Rudholm, PM Hellström, E Näslund, ... British journal of pharmacology 150 (1), 58-64, 2007 | 141 | 2007 |
Increased gut cholinergic activity and antagonism of 5-hydroxytryptamine M-receptors by BRL 24924: potential clinical importance of BRL 24924. GJ Sanger British journal of pharmacology 91 (1), 77, 1987 | 140 | 1987 |
Ghrelin and motilin receptors as drug targets for gastrointestinal disorders GJ Sanger, JB Furness Nature Reviews Gastroenterology & Hepatology 13 (1), 38-48, 2016 | 137 | 2016 |
5‐Hydroxytryptamine and functional bowel disorders GJ Sanger Neurogastroenterology & Motility 8 (4), 319-331, 1996 | 131 | 1996 |